IP Library Granted Patent US 8,962,799
Granted Patent B2
US 8,962,799 · App. 14/446,220 · Granted Feb 24, 2015

Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,799
App. No.
14/446,220
Granted
Feb 24, 2015
Kind
B2
Abstract

A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject.

Claims (36)

1. A method of imaging a region in a subject, the method comprising: administering to the subject a complex comprising a metal chelated to a compound, and obtaining an image of the region in the subject, wherein the compound is represented as:

a pharmaceutically acceptable salt thereof;

f is an integer from 0 to 12; and

g is an integer from 0 to 12.

2. The method of claim 1 , wherein f is 2 to 10.

3. The method of claim 1 , wherein f is 4.

4. The method of claim 1 , wherein g is 2 to 10.

5. The method of claim 1 , wherein g is 4.

6. The method of claim 1 , wherein the compound is:

a pharmaceutically acceptable salt thereof.

7. The method of claim 6 , wherein f is 4.

8. The method of claim 1 , wherein the compound is:

a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein f is 4.

10. The method of claim 1 , wherein the compound is:

a pharmaceutically acceptable salt thereof.

11. The method of claim 10 , wherein g is 4.

12. The method of claim 1 , wherein the compound is:

a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein g is 4.

14. The method of claim 1 , wherein the metal is a radionuclide.

15. The method of claim 14 , wherein the radionuclide is technetium-99m, rhenium-188, or rhenium-186.

16. The method of claim 15 , wherein the radionuclide is technetium-99m.

17. The method of claim 15 , wherein the radionuclide is rhenium-188.

18. The method of claim 15 , wherein the radionuclide is rhenium-186.

19. The method of claim 1 , wherein the obtaining the image comprises using positron emission tomography (PET).

20. The method of claim 1 , wherein the obtaining the image comprises using single photon emission computed tomography (SPECT).

21. A complex comprising a metal chelated to a compound, wherein the compound is represented as:

a pharmaceutically acceptable salt thereof;

f is an integer from 0 to 12; and

g is an integer from 0 to 12.

22. The complex of claim 21 , wherein the metal is a radionuclide.

23. The complex of claim 22 , wherein the radionuclide is technetium-99m, rhenium-188, or rhenium-186.

24. The complex of claim 23 , wherein the radionuclide is technetium-99m.

25. The complex of claim 23 , wherein the radionuclide is rhenium-188.

26. The complex of claim 23 , wherein the radionuclide is rhenium-186.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC
Reel/Frame 062047/0915 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Aug 19, 2020
From: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY LLC
To: WELLS FARGO BANK, N.A.
Reel/Frame 053538/0666 →